| T |
| Tabakman U. U. |
- |
Changes in hemostatic system in oncogynecologic patients |
| Tabares A. |
- |
Co-prescription of drugs with potential interaction with oral anti-coagulants in a health maintenance system from Córdoba, Argentina |
| Tabone M. O. |
- |
Genetic analysis of hereditary factor X deficiency in a French patient of Sri Lanka ancestry: in vitro expression study identified Gly366Ser substitution as the molecular basis of the dysfunctional factor X |
| Tadokoro S. |
- |
The scaffold function of b3 integrins regulates integrin signaling |
| Tadtaeva Z. G. |
- |
Genetic features of thrombophilia in pediatric patients with migraine |
| Tagariello G. |
- |
Intron 1 factor VIII gene inversion in patients with severe hemophilia A |
| Tagariello G. |
- |
Contemporary total hip and knee replacement in A patients with haemophilia and high titre of inhibitors to FVIII by using recombinant FVIIa (novoseven) continuous infusion |
| Tagariello G. |
- |
Molecular genotyping of the Italian cohort of patients with hemophilia B |
| Tagliabue L. |
- |
Lack of association between the annexin V gene -1C®T polymorphism and acute myocardial infarction in 150 young Italian women |
| Tagliaferri A. |
- |
Guidelines on management of nontherapeutic INRs: are really easy to apply in daily practice? |
| |
- |
An alternative model for management of oral anticoagulant therapy: role of general practitioners with support of a computerized system and a portable coagulometer |
| |
- |
Inferior vena cava filters: personal experience on 322 devices, with regard also to medical treatment during long-term follow-up |
| |
- |
Efficacy of Haemate P in the management of patients with von Willebrand disease undergoing surgery |
| |
- |
Plasma-derived FXIII concentrate is as safe and effective as placenta-derived FXIII concentrate for the treatment of inherited FXIII deficiency |
| Taguchi O. |
- |
C-reactive protein induces the expression of tissue factor and interleukin-8 in the lung |
| Taher A. |
- |
Prevalence of factor V Leiden, MTHFR C677T and prothrombin G20210A mutations in Lebanese thalassemia intermedia patients |
| |
- |
High prevalence of prothrombin G20210A mutation among patients with deep venous thrombosis in Lebanon |
| Taher A. |
- |
Congenital afibrinogenemia: expression and analysis of novel mutations affecting fibrinogen assembly or secretion |
| |
- |
Nine years experience at the AUB-MC vascular lab |
| Taioli E. |
- |
Embryo implantation after assisted reproductive procedures and maternal thrombophilia |
| Tait R. |
- |
Coagulation activation markers in atrial fibrillation: dose-dependent correlation with warfarin therapy |
| Tait R. C. |
- |
Population prevalence of atrial fibrillation and factors associated with use of warfarin |
| Tait R. C. |
- |
The prevalence of, and molecular defects underlying, inherited Protein S deficiency in the general population |
| |
- |
Evaluation of the role of genetic analysis in dysfibrinogenemia |
| Taka T. |
- |
GTT: A comprehensive in vitro haemostasis test, assessing platelet function, coagulation and thrombolytic activity from a single native blood sample |
| |
- |
Impaired flow-mediated vasodilation in vivo and reduced shear-induced platelet reactivity in vitro in response to nitric oxide in prothrombotic, stroke-prone spontaneously hypertensive rats |
| Takada K. T. |
- |
Oxidized phospholipids in oxidized LDL down-regulate thrombomodulin transcription in vascular endothelial cells through a decrease in the binding of RAR |
| Takafuta T. |
- |
Mechanisms of platelet retention in the collagen-coated bead columns |
| Takagi A. |
- |
Ryudocan (syndecan-4) deficiency increases susceptibility to LPS-induced shock in mice |
| Takahashi Y. |
- |
Activated factor VII enhances whole blood fibrinolysis due to urokinase-type plasminogen activator |
| Takahashi T. |
- |
Plasminogen activator inhibitor-1 promotes fibrosarcoma cell migration by modifying cellular attachment to vitronectin via a vb 5 integrin |
| Takahashi K. |
- |
Factor VIIa directly promotes thrombin burst in the presence of negatively charged phospholipids and factor Va |
| Takayama T. |
- |
Factor VIIa directly promotes thrombin burst in the presence of negatively charged phospholipids and factor Va |
| Takayama H. |
- |
Platelet GP VI can be new anti-platelet target for prevention of acute coronary syndrome |
| Takeda M. |
- |
Synthetic inhibitors of coagulation factor Xa suppress thrombin generation without affection on initial thrombin forming time |
| Takeshita K. |
- |
Ryudocan (syndecan-4) deficiency increases susceptibility to LPS-induced shock in mice |
| Takeyama M. |
- |
M-thrombin (Tris-coupled thrombin) is a novel potent agonist of platelet activation with minimum effect on clot formation |
| |
- |
Factor V C2 domain contains major binding site for thrombin |
| Taki M. |
- |
Mechanism of decreased plasma von Willebrand Factor-cleaving metalloproteinase activity in patients with collagen vascular disease |
| Takio K. |
- |
Purification and identification of coagulation factor IX-activating enzyme on the erythrocyte membranes |
| Tal Y. |
- |
Efficacy and safety of two doses of enoxaparin in pregnant women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX study |
| Talbot J. A. |
- |
A humanized monoclonal antibody against vWF A1 domain inhibits vWF:RiCof activity and platelet adhesion in human volunteers |
| Taliani R. |
- |
Interaction between thrombophilic genetic mutations and clinical bleeding in patients undergoing chronic oral anti-coagulant treatment |
| Taliani M. R. |
- |
Long-term clinical outcome of patients with pulmonary embolism: a prospective, multicenter study |
| Taliani M. R. |
- |
Incidence of newly diagnosed cancer after three months or one year of oral anticoagulation for a first episode of idiopathic venous thromboembolism |
| Taliani M. R. |
- |
Visceral vein thrombosis: retrospective analysis of 53 cases in five Italian thrombosis |
| Taliani M. R. |
- |
Prevalence of thrombophilic genetic mutations in patients undergoing thrombotic events while on oral anticoagulants: a case-control study |
| Tamarin I. |
- |
Monitoring the combined effect of integrilin, clopidogrel and aspirin in patients with myocardial infarction by Cone and Plate(let) Analyzer |
| Tamioulaki A. |
- |
Treatment of DIC: the role of PC |
| Tammiste I. |
- |
Vipera lebetina factor X activating enzyme – cloning and sequencing |
| Tamura S. |
- |
Combination of increased vascular thrombogenesity and blood flow alteration promote obstructive thrombus formation in rabbit femoral artery |
| Tamura N. |
- |
Dissolving effects of anti-GP IIb/IIIa agents on platelet thrombi formed on the collagen surface under blood flow conditions |
| Tamura N. |
- |
Real-time visualization of platelet shape changes occurring in response to their adhesion on immobilized type I collagen or von willebrand factor under controlled blood flow conditions |
| Tamura N. |
- |
Platelet GP VI can be new anti-platelet target for prevention of acute coronary syndrome |
| Tamura N. |
- |
Imaging and characterization of the procoagulant activity appeared on the surface of platelet thrombi formed on the collagen surface under blood flow conditions |
| Tan T. |
- |
Protein Z-dependent protease inhibitor (ZPI) deficiency: a new thrombotic risk factor? |
| Tanabe T. |
- |
Platelet GP VI can be new anti-platelet target for prevention of acute coronary syndrome |
| |
- |
Imaging and characterization of the procoagulant activity appeared on the surface of platelet thrombi formed on the collagen surface under blood flow conditions |
| |
- |
Real-time visualization of platelet shape changes occurring in response to their adhesion on immobilized type I collagen or von willebrand factor under controlled blood flow conditions |
| Tanaka I. |
- |
Factor V C2 domain contains major binding site for thrombin |
| Tanaka H. |
- |
Elevated plasma levels of fibrin degradation products by granulocyte-derived elastase in patients with DIC |
| Tanaka I. |
- |
The hemostatic effectiveness of regular infusions of factor VIII concentrates in hemophilia A patients with high responder inhibitors |
| Tanaka M. |
- |
The hemostatic effectiveness of regular infusions of factor VIII concentrates in hemophilia A patients with high responder inhibitors |
| Tanaka Y. |
- |
Intracellular behavior of anti-thrombin Morioka (Cys95Arg), a mutant protein causing type I deficiency: escape from intracellular protein degradation systems and accumulation within newly formed Russell's body-like structures |
| Tanaka A. |
- |
Platelet-derived microparticle preparations for enzyme-linked immunoassay, and the high PDMP level detected in unstable angina patients |
| Tanaka I. |
- |
Hemophilia A gene therapy using the third-generation lentiviral vector – Mouse model |
| Tandi C. |
- |
P-selectin-dependent lung colonization of melanoma cells is targeted by heparin treatment |
| Tanduo C. |
- |
The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study |
| Tang I. |
- |
Safety and tolerability of argatroban anticoagulation in patients with end-stage renal disease undergoing hemodialysis: a prospective study |
| Tang H. |
- |
Soluble platelet GPV: a new marker of thrombosis status |
| Tangnararatchakit K. |
- |
The use of recombinant activated factor VII for controlling life-threatening bleeding in dengue shock syndrome |
| Tani Y. |
- |
Effects of CS-747, a novel P2Y12 receptor antagonist, on cerebral and peripheral arterial occlusive diseases in rats |
| Tani T. |
- |
Different distribution of antithrombin and thrombomodulin in endotoxin-treated rat: effect of antithrombin and activated protein c concentrates and nafamostat mesilate |
| Tanii M. |
- |
Platelet-derived growth factor receptor-alpha signaling is required for therapeutic angiogenesis induced by fibroblast growth factor-2 |
| Tanii M. |
- |
Recombinant sendai virus-mediated intramuscular gene transfer of FGF-2 restores collateral blood perfusion of chronically ischemic rabbit hind limb, and inhibits neointimal hyperplasia of autologous femoral vein grafts |
| Tanii M. |
- |
Involvement of VEGF-C/flt-4 system in therapeutic angiogenesis of FGF-2 gene transfer in murine ischemic hind limb |
| Tanis B. |
- |
Procoagulant factors and the risk of myocardial infraction in young women |
| Tanis B. C. |
- |
Estrogens, progestogens and thrombosis |
| Tannatt M. |
- |
Application of a novel polypeptide affinity ligand for purification of recombinant FVIII |
| Tanoue K. |
- |
Insulin enhances human monocyte tissue factor expression induced by activated platelets via phosphatidylinositol-3-kinase signaling pathway |
| |
- |
The functional profiles of circulating T lymphocytes distinguishes patients with stable angina and unstable angina |
| |
- |
Lower activation of circulating platelets after implantation of Toyobo LVAS was associated with lower incidence of thromboembolism: a comparison with Novacor LVAS |
| |
- |
HLA-DR and CD40 ligand expressing T-lymphocytes are increased in circulation in patients with idiopathic dilated cardiomyopathy |
| Tans G. |
- |
Changed inactivation pathway of factor Va by activated protein C in the presence of heparin |
| |
- |
Venous thrombosis and APC resistance during hormone treatment in male-to-female transsexuals |
| |
- |
Functional properties of recombinant factor Va mutated in a potential calcium-binding site |
| |
- |
Functional characterization of recombinant factor V molecules mimicking the R2-haplotype |
| Hackeng T.M. |
- |
Functional impairment of protein S in carriers of the prothrombin G20210A mutation |
| Tans G. |
- |
Impaired anticoagulant activity of factor V accounts for a large fraction of the APC resistance associated with the FV Leiden (R506Q) and R2 (H1299R) mutations |
| |
- |
Activated factor V is inactivated by activated protein C in the absence of APC cleavage sites at Arg306, Arg506 and Arg679 |
| |
- |
Enhanced thrombin generation and mild bleeding tendency in a severely FVII-deficient patient carrying FV Leiden |
| |
- |
Endogenous factor V synthesis in megakaryocytes contributes negligibly to the platelet factor V pool |
| Tanski W. |
- |
Phosphorylation of platelet proteins in hemodialysed patients is different than in control donors |
| Taouaf A. |
- |
The mannometric profile of native arteriovenous fistulas in the Avicenne Hemodialysis Center of Casablanca (preliminary results) |
| Tapon-Bretaudière J. |
- |
Functional consequences of a factor VII gene donor splice site mutation causing a lethal factor VII deficiency: regulation in the splice site selection |
| Tappenden K. |
- |
Contact system activation, FXIIa and plasma kallikrein produce enhanced fibrinolysis in urokinase induced fibrinolysis in thromboelastography: (UKIFTEG) |
| |
- |
Urokinase induced fibrinolysis in thromboelastography (UKIFTEG): a new assay for determining fibrinolysis in whole blood |
| Tapson V. |
- |
Non-invasive detection of proximal DVT using bilateral compression ultrasound: methodology for the EXCLAIM study |
| Tapson V. F. |
- |
Acute deep vein thrombosis: A prospective registry of 5451 patients |
| Tapson V. |
- |
Extended thromboprophylaxis with enoxaparin in acutely ill medical patients with prolonged periods of immobilisation: the EXCLAIM study |
| |
- |
A risk assessment model for identifying medical patients who should receive thromboprophylaxis |
| |
- |
The impact of thromboembolism |
| |
- |
A multinational observational cohort study in hospitalized medical patients of practices in prevention of venous thromboembolism and clinical outcomes: findings of the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) |
| Taralunga C. |
- |
Phenotypic sensitivity to activated protein C in healthy families: importance of genetic components and environmental factors in the Stanislas Cohort |
| Tarantino M. |
- |
Continuing clinical evaluation of an advanced category recombinant FVIII, antihemophilic factor (recombinant) plasma/albumin-free method (rAHF-PFM) in previously treated patients (PTPs) |
| Tarantino N. |
- |
Fractalkine/CX3CL1 production by human aortic smooth muscle cells impairs monocyte procoagulant and inflammatory responses |
| Tarantino M. |
- |
Evaluation of rAHF-PFM in previously treated patients |
| Tarantino M. |
- |
Recombinant FVIIa promotes adhesion and aggregation of platelets in normal subjects and von Willebrand disease patients as measured in the PFA100™ |
| Tarantino M. D. |
- |
Recombinant FVIIa promotes adhesion and aggregation of platelets in normal subjects and von Willebrand disease patients as measured in the PFA100™ |
| Tarasova T. |
- |
The effect of clopidogrel on walking distance and hemostasis in patients with intermittent claudication |
| Tardtong P. |
- |
Prevalence of Arg 506 and Arg 306 mutations of the factor V gene in Thai blood donors |
| Tardy B. |
- |
Clinical experience with optional cava filters |
| |
- |
Risk factors of major hemorrhages during treatment of acute DVT: results from 5 randomized trials |
| |
- |
Predictive factors of cancer discovery after deep-vein thrombosis: a 8-years follow-up study |
| Tarumi T. |
- |
Synthetic inhibitors of coagulation factor Xa suppress thrombin generation without affection on initial thrombin forming time |
| Tasiopoulou K. |
- |
Thrombophilic tendency in patients with chronic renal disease submitted to regular dialysis |
| Tassanawiwat P. |
- |
Detection of the factor XIIIA Val34Leu polymorphism in Thais |
| Tassies D. |
- |
Polymorphisms of platelet glycoproteins Ib-a and Ia/IIa: relationship with early arteriosclerosis and arterial thrombosis in patients with the antiphospholipid syndrome or with systemic lupus erythematosus |
| Tassies D. |
- |
Effect of antiphospholipid antibodies in the activation of the contact complex: importance in the obstetric complications of the antipospholipid syndrome |
| Tatsumi F. |
- |
Usefulness of the prothrombin level measured by the carinactivase-1 method as the parameter of the coagulation activity during chronic warfarin therapy |
| Tatsumi K. |
- |
Factor V C2 domain contains major binding site for thrombin |
| Tatsumi F. |
- |
The functional profiles of circulating T lymphocytes distinguishes patients with stable angina and unstable angina |
| Tavarela Veloso F. |
- |
A different view on the inflammatory bowel disease – the role of adhesion molecules and angiogenic growth factors |
| Tavella M. H. |
- |
Thrombotic risk in first-degree relatives of factor V Leiden (FVL) and factor II G20210A carriers |
| |
- |
Factor XIII (FXIII) Val34Leu, His95Arg and G30899A polymorphisms and the risk of deep venous thrombosis |
| Taylor R. S. |
- |
Inherited thrombophilias are not increased in ‘idiopathic’ small for gestational age pregnancies |
| Taylor D. |
- |
The peptide LSARLAF directly induces a conformation change in the platelet integrin aIIbb3 |
| Taylor J. M. |
- |
The high frequency and specificity of the Lupus cofactor effect in a dPT screen |
| Taylor F. B. |
- |
Alterations in lipoprotein homeostasis during experimental and clinical sepsis in primates |
| Taylor J. |
- |
Hypercoagulability in inflammatory bowel disease |
| Taylor Jr F. |
- |
Early control of the first stage of the response to LD100 E. coli may optimize the therapeutic effect of activated protein C |
| TBA |
- |
Current Concepts of the Pathophysiology and Management of Sepsis |
| Tbakhi A. |
- |
Single center review of clinicopathological characterization in 77 patients with positive lupus anticoagulant antibodies |
| Tcheng J. E. |
- |
Rapid point-of-care assessment of enoxaparin activity during percutaneous coronary interventions: the ELECT study |
| Tchernia G. |
- |
Clinical and laboratory findings in a new case of congenital amegakaryocytic thrombocytopenia (CAMT) |
| te pOele M. |
- |
Hyperhomocysteinemia: risk factor or consequence of venous thrombosis? |
| Teeraratakul S. |
- |
Successful use of recombinant activated factor VII for controlling bleeding in patients receiving invasive surgeries |
| Teixeira M. A. |
- |
Glanzmann thrombasthenia: a study of two Portuguese families and identification of a new homozygous C insertion in exon 10 of the GPIIIa |
| Tekelenburg W. L. |
- |
Dimers of b2-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2: an explanation for arterial thrombosis in the anti-phospholipid syndrome |
| Tellini I. |
- |
Protein Z levels in acute coronary syndromes |
| Tembl J. |
- |
Insufficient thromboxane A2 inhibition in patients with vascular disease chronically treated with aspirin: implications for platelet function |
| Temmler U. |
- |
Activated platelets and platelet-derived microvesicles (PMV) transfer tissue factor (TF) to monocytes but not to neutrophils |
| Temple M. |
- |
Central venous catheter (CVC) related thrombosis in boys with hemophilia |
| Temple I. |
- |
Increase in platelet VEGF release in early breast cancer |
| Temple M. |
- |
Vena cava filters in children: review of a single centre clinical experience over 7 years |
| ten cate H. |
- |
Effect of hyperhomocysteinemia on coagulation activation and endothelial cell activation |
| Ten Cate H. |
- |
Effect of pravastatin on plasma markers of coagulation and inflammation in type 2 diabetes |
| tEn cAte J. |
- |
Lepirudin anti-coagulation in critically ill patients with (suspected) heparin-induced thrombocytopenia and thrombosis |
| Ten Cate H. |
- |
Endothelial cell and monocyte-derived microparticles in severe dengue virus infections |
| ten cate H. |
- |
A two-stage thrombophilia screening protocol: more efficient use of laboratory tests |
| Ten Cate H. |
- |
A functional single-nucleotide polymorphism in the thrombin-activatable fibrinolysis inhibitor (TAFI) associated with risk and outcome of meningococcal disease (MD) |
| |
- |
Rapid arterial thrombus formation after endothelial injury in streptozotocin-induced diabetic mice |
| |
- |
Elevated steady state serum sVCAM-1 levels occur from an early age in sickle cell patients, but are not related to vasoocclusive crises and acute chest syndrome frequency |
| |
- |
Symptomatic plaques of type 2 diabetic patients show more plaque complications but similar expression patterns of markers for coagulation and inflammation compared to nondiabetic controls |
| |
- |
Reduced protein C and S activity and sickle cell disease severity |
| |
- |
Levels of endothelial activation markers, D-dimer fragments and pro-inflammatory cytokines and sickle cell disease severity |
| Ten Klooster J. |
- |
The small GTP-binding protein Ral is involved in cAMP-mediated release of VWF from endothelial cells |
| Ten Wolde M. |
- |
Brain natriuretic peptide (BNP) as a predictor of adverse outcome in patients with pulmonary embolism |
| |
- |
High levels of coagulation factors IX or XI: risk factors for pulmonary embolism? |
| Ten Wolde M. |
- |
The prevalence and prognostic importance of elevated cardiac troponins in patients with acute submassive pulmonary embolism |
| |
- |
d-dimer as a prognostic marker in patients with pulmonary embolism |
| |
- |
Screening of high factor VIII levels is not recommended in patients with recently diagnosed pulmonary embolism |
| Tencati M. |
- |
Role of cardiac myocyte tissue factor in hemostasis in the heart |
| Tenchini M. L. |
- |
Congenital afibrinogenemia, identification of four novel homozygous mutations in the fibrinogen gene cluster: three point mutations and a 15-kb deletion |
| |
- |
Allelic heterogeneity of severe factor V deficiency: doubling of the mutational spectrum of the factor V gene, and expression of the identified missense mutations |
| Tengborn L. |
- |
In vivo monitoring of hemophilia A patients with inhibitors under recombinant factor VIIa therapy |
| Tennenbaum G. |
- |
The hemostatic balance between tissue factor (TF) and tissue factor pathway inhibitor (TFPI) in cultures of human primary trophoblasts |
| Tenno T. |
- |
A sensitive method for tissue factor mRNA quantitation |
| Teodoridis A. |
- |
Platelet receptor polymorphisms of glycoprotein (GP) Iba VNTR, GP IIb-IIIa (HPA–1), and GP Ia C807T and the risk of premature myocardial infarction |
| Teodoridis T. |
- |
C-reactive protein: a link between inflammation and thrombosis formation in patients with unstable angina? |
| Tepeneu P. |
- |
Medical and surgical approach of pseudotumours and blood cysts in hemophiliacs without primary prophylactic replacement therapy |
| Teplyakov A. I. |
- |
Fluid shear stress, blood coagulation and epigenome topography of lymphocytes at atherosclerosis: changes of gene expression? |
| Teplyakov A. I. |
- |
Carbon disulfide and low-level ionizing irradiation: causes of hypercoagulable state, impair cell–cell communication and accelerated atherosclerosis |
| Terada Y. |
- |
Different distribution of antithrombin and thrombomodulin in endotoxin-treated rat: effect of antithrombin and activated protein c concentrates and nafamostat mesilate |
| Teran N. |
- |
The frequencies of fibrinogen polymorphisms Taq I, Hae III and Bcl I in patients with deep-vein thrombosis |
| Terbizan M. |
- |
Safety of the transfer of patients on anticoagulant therapy from hospital anticoagulant clinics to general practitioners using a computer-decision support |
| Terraube V. |
- |
Increased metastatic potential of tumor cells in von Willebrand factor (VWF)-deficient mice |
| Terrell D. R. |
- |
Long-term outcomes following recovery from thrombotic thrombocytopenic purpura – hemolytic uremic syndrome (TTP-HUS) measured by health-related quality-of-life (QOL) assessments |
| Terrisse A. D. |
- |
Shedding of active tissue factor (TF) by rat aortic smooth muscle cells (SMCs) undergoing apoptosis |
| Terry C. M. |
- |
Polymorphisms in the 5'UTR of the tissue factor (TF) gene are associated with differences in total and surface clotting activity and TF mRNA of endothelial cells |
| Terry C. M. |
- |
Inflammatory modulation of alveolar coagulation inhibition in a mouse model of acute respiratory distress syndrome (ARDS) |
| Terry C.F. |
- |
Haplotype and tissue-specific control of interleukin-6 expression and the implications in athero-thrombotic disease |
| Terstappen L. W. M. M. |
- |
Standardization of circulating endothelial cell enumeration in whole blood |
| Tesorone M. |
- |
Transdermal hormone replacement therapy does not affect hemostasis and inflammation |
| Tesselaar M. |
- |
Incidence of thrombosis in gastro-esophageal cancer: a cohort study of 649 patients |
| Testa S. |
- |
Clinical quality assessment program for the oral anti-coagulant clinic: preliminary report of a multicentric Italian exercise |
| Tetreault R. |
- |
Hemophilia A: total correction in mice and partial correction in dogs with canine FVIII using a new AAV serotype |
| Teuma X. |
- |
Immuno-phenotypic platelet characteristics distinguish high vs. low risk patients for thrombosis after stent implantation under thienopyridin plus aspirin treatment |
| |
- |
Interest of VASP measurement on patients treated by thienopyridines |
| Th M. |
- |
Antigenic characterization of endothelial cell-derived microparticles and their detection ex vivo |
| Thaler I. |
- |
Efficacy and safety of two doses of enoxaparin in pregnant women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX study |
| Thalhammer A. |
- |
Contrast media and compounds containing iodine prevent fibrin formation |
| Thames E. H. |
- |
Sensitivity and specificity of the abnormal optical waveform profile in the prothrombin time from patients with antiphospholipid antibodies |
| |
- |
Clinical trial to evaluate the safety and efficacy of an Internet-based system for supervised self-management of oral anti-coagulant therapy |
| Thanarattanakorn P. |
- |
The use of recombinant activated factor VII for controlling life-threatening bleeding in dengue shock syndrome |
| Thanassi N. M. |
- |
Factor V endocytosed and retained by megakaryocytes is specifically proteolytically processed by an intracellular protease to form the platelet-derived factor V pool |
| Thanyachai S. |
- |
The factor V R2 allele (A4070G), factor V gene G1628A mutation, factor V Hong Kong (A1090G), factor V Cambridge (G1091C), the tissue factor pathway inhibitor gene C536T mutation and the risk of venous thrombosis in Thai patients |
| Thattaliyath B. D. |
- |
Role of two populations of thrombocytes in arterial thrombosis in zebrafish |
| Thayer E. |
- |
Agreement between FXIII activity assays and calibrator plasma pools: the need for a FXIII reference standard with regulatory recognition |
| The French Haemostasis Group, GEHT |
- |
Age influence on D-Dimer in a large normal French population: the FITENAT study |
| The Matisse Investigators |
- |
The MATISSE-DVT trial, a randomized, double-blind study comparing once-daily fondaparinux (Arixtra®) with the low-molecular-weight heparin (LMWH) enoxaparin, twice daily, in the initial treatment of symptomatic deep-vein thrombosis (DVT) |
| |
- |
The MATISSE-PE trial, a multicenter, randomized, open study comparing once-daily fondaparinux (Arixtra®) with adjusted-dose intravenous unfractionated heparin (UFH) in the initial treatment of acute symptomatic pulmonary embolism (PE) |
| Theakston R. D. G. |
- |
Characterization of novel platelet and procoagulant activities from Bothrops cotiara snake venom |
| Theodoropoulos J. |
- |
Haematologic factors potentially implicated in the pathophysiology of avascular necrosis of the femoral head (AVN): hypercoagulability as a cause of AVN |
| Theodorou E. |
- |
Comparison and diagnostic value of two different D-dimer methods in the clinical laboratory |
| Theophilus B. |
- |
Are there really undetectable Factor VIII mutations in hemophilia A? How can we deal with the difficult ones? |
| Theophilus B. D. M. |
- |
Identification of factor IX mutations in 17 Iranian families with hemophilia B |
| Theroux P. |
- |
Inter-individual variability in inhibition of platelet activation and aggregation by clopidogrel |
| Thiagarajan P. |
- |
Tissue factor-bearing microparticles arise from monocyte lipid rafts and can fuse with activated platelets, consolidating all of the membrane-bound coagulation reactions on the platelet surface |
| Thibault G. |
- |
Demonstration of a tissue factor pathway inhibitor-2 (TFPI-2) mRNA synthesis by pure villous cytotrophoblast cells isolated from term human placentas |
| Thiec F. |
- |
Role of the Gla and first EGF-like domains of Factor X in the Prothrombinase and Tissue Factor-Factor VIIa complexes |
| |
- |
The substitution of the factor Xa a-helix 345–352, which is a factor Va interactive site, by the corresponding structure of factor IXa does not affect formation and activity of the prothrombinase complex |
| Thijssen H. H. W. |
- |
Variations of INR and Factor VII Level are linked to Cytochrome P450 2C9 genotype |
| Thiruchelvam A. |
- |
Prevalence of Factor V Leiden and Prothrombin G20210A Mutations in Malaysian patients with thromboembolic disorders |
| Thivolet-Bejui F. |
- |
Identification and characterisation of MIP-1b and VE-Cadherin as important markers of acute rejection after human heart transplantation |
| Thom J. Y. |
- |
Anti-phospholipid antibodies in ischemic stroke |
| |
- |
Normal platelet-poor plasma correction studies in the laboratory diagnosis of lupus anticoagulant |
| Thomas S. |
- |
Influence of flow on inhibition of platelet dependent thrombin generation by an anti-GPIIb/IIIa antibody |
| Thomas C. V. |
- |
b3-integrin deficiency and antibody-mediated b3-integrin inhibition have paradoxical effects on murine smooth muscle cell proliferation and the development of intimal hyperplasia after vascular injury |
| Thomas E. |
- |
New chromogenic screening assay for detecting deficiencies in protein C and protein S |
| Thomas L. |
- |
The role of TAFIa in relation to serpin inhibitors of fibrinolysis |
| Thomas D. |
- |
Quantification of the platelet-generating demarcation membrane system in living megakaryocytes |
| Thomas S. |
- |
Influence of R353Q factor VII gene polymorphism on the plasma FVII levels in a French native population (The Fitenat Study) |
| Thomas L. |
- |
The C-terminus of a 2-anti-plasmin: effect on fibrinolysis |
| Thomas J. M. |
- |
Evidence for a role of tachykinins in the regulation of human platelet activation |
| Thomas E. |
- |
A new screening assay for abnormalities in the Protein C anticoagulant pathway |
| Thomassen M. |
- |
Endogenous factor V synthesis in megakaryocytes contributes negligibly to the platelet factor V pool |
| Thomassen M. C. L. G. D. |
- |
Venous thrombosis and APC resistance during hormone treatment in male-to-female transsexuals |
| Thompson M. |
- |
Prevention of thromboemboli by enhancing fibrinolysis: a possible therapeutic mechanism of action for Dextran-40 |
| Thompson J. L. P. |
- |
Thrombin generation after ischemic stroke: the hemostatic system activation study (HAS) |
| Thompson P. |
- |
Thrombotic thrombocytopenic purpura in a patient with acquired vWF protease (ADAMTS13) deficiency was heralded by variable stimuli and lacked a good correlation between platelet counts and vWF protease levels |
| Thompson A. R. |
- |
Recombinant factor VIII C1C2 domain expressed in E. coli |
| Thompson E. |
- |
Factor V Gly2112Asp, a C2-domain variant, is associated with severe deficiency and a bleeding tendency |
| Thomson P. D. |
- |
Ethnic differences in the frequencies of polymorphisms of protein S and protein C in South African populations |
| Thong B. |
- |
Binding of covalent antithrombin–heparin complex to endothelial cells |
| Thoreson A. |
- |
Activation of neutrophils by antibodies generated in heparin-induced thrombocytopenia |
| Thornell B. J. |
- |
Thrombin generation after ischemic stroke: the hemostatic system activation study (HAS) |
| Thornton M. A. |
- |
Murine (m) aIIb out-competes human (h) aIIb for mouse b3 in a transgenic mouse model: Implications for integrin subunit interactions |
| Thorpe P. E. |
- |
Basal levels of phosphatidylserine exposure on the cell-surface of T-lymphoblastoid and monocytoid cells: relationship to Prothrombin and FX activation, and Tissue Factor activity |
| |
- |
The use of phospholipid-dependent clotting assays to characterize the cell-surface procoagulant activities of T-lymphoblastoid cell lines |
| Thorrez L. |
- |
Gene therapy for hemophilia A with high-capacity adenoviral vectors: preclinical evaluation in hemophilic mice and dogs |
| Thrive III Investigators |
- |
Extended secondary prevention with the oral direct thrombin inhibitor ximelagatran for 18 months after 6 months of anticoagulation in patients with venous thromboembolism: a randomized, placebo-controlled trial |
| Thuerlemann C. |
- |
Development of a biosensor system for self-testing the intensity of anti-coagulation by anti-coagulated patients in capillary whole blood |
| Thumpston J. |
- |
Elevated factor VIIIC level is a major risk factor for venous thrombo-embolism in the black population |
| Thurlow P. |
- |
Mechanism of activation in Eastern tiger snake bite |
| Thyberg J. |
- |
Influence of intraluminal thrombus on cellular and structural features of the aneurysm wall |
| Thys C. |
- |
The Gs agonist PACAP(1–38) is a physiological inhibitor of platelet aggregation and megakaryocyte maturation |
| |
- |
Functional polymorphisms in the paternally expressed XLas and its cofactor ALEX decrease their mutual interaction and enhance receptor-mediated cAMP formation resulting in platelet Gs hyperfunction |
| Thyzel E. |
- |
Quantification of tissue factor pathway inhibitor (TFPI) in human seminal plasma and in human ovarian follicular fluid |
| |
- |
Expression of wild type tissue factor pathway inhibitor (TFPI) and the first natural TFPI mutant ([P151L]) in insect and mammalian cells |
| Tick L. W. |
- |
The assessment of pretest probability in patients with suspected Deep-Vein Thrombosis is of great value in nonacademic teaching hospitals |
| |
- |
Post-thrombotic complaints are not related to factor V Leiden mutation or elastic compression stockings: results of the MEGA Study |
| Tiede M. |
- |
Successful outcome of rituximab therapy for spontaneous refractory high titer FVIII inhibitors |
| Tien S. L. |
- |
Radioisotopic synovectomy and haemophilic arthropathy in Asians: a retrospective study |
| |
- |
Projection parameters for usage of blood products in Singapore General Hospital |
| Tien S. L. |
- |
Clinical profile of rare coagulation disorders in an Asian population |
| Tien S. L. |
- |
Thrombotic events associated with the use of recombinant factor VIIa in a single institution: a role for caution |
| Tillmann I. F. |
- |
The effect of BIBR 953 ZW, the active form of the oral direct thrombin inhibitor BIBR 1048, on the prolongation of aPTT and ECT in orthopedic patients: a population pharmacodynamic study |
| Timms J. M. |
- |
Basal Fibrinogen and FVIII:C Concentrations are not Associated with Polymorphisms in the Interleukin-1 Gene Cluster |
| Tincani A. |
- |
European forum on antiphospholipid antibodies standardization group: results of the 2nd round on antibeta2glycoprotein I home-made assays |
| Tinlin S. |
- |
Treatment of severe canine hemophilia A by helper-dependent adenoviral-mediated gene therapy |
| |
- |
The use of three hemophilia A mouse models to illustrate strain-specific differences in immune responses to FVIII protein replacement via protein infusion or adenoviral gene therapy |
| Tinneberg H. R. |
- |
Quantification of tissue factor pathway inhibitor (TFPI) in human seminal plasma and in human ovarian follicular fluid |
| Tiozzo F. |
- |
Symptomatic chronic thromboembolic pulmonary hypertension after symptomatic pulmonary embolism: incidence and risk factors: a long-term follow-up study |
| Tipping P. G. |
- |
The cytoplasmic domain of tissue factor contributes to leukocyte recruitment and death in endotoxemia |
| |
- |
The cytoplasmic domain of tissue factor plays an important role in innate and adaptive immunity |
| Tirado I. |
- |
The 46C®T polymorphism in the F12 gene is a risk factor for ischemic stroke |
| Tirado I. |
- |
The 46C®T polymorphism in the F12 gene as a risk factor for venous thrombosis: association after linkage analysis |
| Tirado I. |
- |
The 46C®T polymorphism in F12 gene is a risk factor for coronary artery disease |
| Tiraferri E. |
- |
Perioperative management with low molecular weight heparin (LMWH) of patients (pts) on long-term oral anticoagulant therapy (OAT) undergoing major surgery: a multicenter prospective observational study |
| Tiret L. |
- |
There is no north/south gradient distribution of the plasma fibrinogen level and of the C-148T Fg genotype in a French native population (The Fitenat Study) |
| |
- |
Differential geographic distribution of Factor V Leiden and Factor II Leiden in a French native population (the Fitenat study) |
| Tischenko E. |
- |
Combined anti-thrombotic protection of vascular wall with bienzyme superoxide dismutase–chondroitin sulphate–catalase conjugate in vivo |
| Titaeva E. |
- |
The influence of exercise and stress on markers of activation of coagulation and fibrinolysis in young postinfarction patients |
| |
- |
The influence of treatment with low molecular weight heparins (dalteparin, nadroparin) on the clinical course and hemostasis activation markers in patients with unstable angina |
| |
- |
Efficacy of 1-year acenocumarol therapy and its relation with gene polymorphism related to thrombophilia in patients with nonvalvular atrial fibrillation |
| |
- |
The effect of clopidogrel on walking distance and hemostasis in patients with intermittent claudication |
| Tjernberg A. P. |
- |
Dimerization and multimerization defects of von Willebrand factor due to mutated cysteine residues |
| Tobu M. |
- |
Malignancy-related thrombotic state is independent of defects in Factor V Leiden, prothrombin 20210 and MTHFR. Results from the initial profiling of cancer patients entering in a secondary prevention of venous thrombosis with enoxaparin (ONCENOX) |
| |
- |
Prevalence of anti-Erythropoietin antibodies in end stage renal disease patients treated with recombinant Erythropoietin |
| |
- |
Heparinase I digestion of tinzaparin: a novel approach to neutralize the anti-coagulant and potential hemorrhagic effects of low molecular weight heparin |
| |
- |
Interaction of thrombolytic agents with argatroban: pharmacological implications |
| |
- |
Molecular-weight dependence on the inhibition of procarboxypeptidase U by heparin and a polydeoxyribonucleotide derived antithrombotic agent (Defibrotide) |
| Tobu M. |
- |
Considerations in the standardization of the functional and immunologic assays for human procarboxypeptidase U. Diagnostic implications |
| Tobu M. |
- |
Plasma procarboxypeptidase U is up-regulated in patients undergoing percutaneous intervention: effects of anticoagulant dosage of low molecular weight heparins |
| Tobu M. |
- |
The irrelevance of International Normalized Ratio in the monitoring of anti-IIa and anti-Xa drugs |
| Tobu M. |
- |
Pharmacodynamics and pharmacokinetics of anti-Xa potency adjusted heparin derived oligosaccharides in nonhuman primates: implications in dosage optimization |
| |
- |
Activated clotting time guided dosage optimization of a low molecular weight heparin (tinzaparin) for surgical and interventional indications |
| |
- |
Inhibition of procarboxypeptidase U by tinzaparin. A potential mechanism of its profibrinolytic actions |
| Tocci G. |
- |
Enhanced TNF-a and oxidative stress in patients with heart failure: effect of TNF-a on platelet O2 production |
| Todini A. R. |
- |
Subcutaneous adjusted-dose unfractionated heparin vs. fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism |
| Todolí J. |
- |
Circulating activated protein C in Behcet's disease and risk of thrombosis |
| Todros T. |
- |
Intruterine Growth Restriction (IUGR) and thrombophilic polymorphisms |
| Tognazzo S. |
- |
The G>T point mutation (Val34Leu) in the Factor XIII-A subunit gene in venous leg ulcers |
| Tognin G. |
- |
The incidence of venous thromboembolism in carriers of single identified prothrombin G20210A: a retrospective cohort study |
| |
- |
The incidence of venous thromboembolism in homozygous or double heterozygous carriers of the factor V Leiden mutation, prothrombin 20210 A mutation and HR2 aplotype: interim report |
| |
- |
The incidence of venous thromboembolism in double-heterozygous carriers of antithrombin, protein C and protein S deficiency and HR2 haplotype |
| |
- |
Levels of anti-thrombin III activity in the plasma of cynomolgus monkeys after administration of recombinant human anti-thrombin III |
| |
- |
Anti-thrombin III levels in cynomolgus monkey recipients of a life-supporting porcine renal xenograft |
| |
- |
Increased TAFI-dependent anti-fibrinolytic effect associated with the presence of an anti-FV antibody in a patient with severe thrombophilia |
| Tognolini M. |
- |
Contact-dependant signalling during late events of platelet activation |
| Toh C. H. |
- |
Detection of Thrombomodulin (TM) Ala455Val polymorphism using sequence-specific primer–polymerase chain reaction (PCR) in patients with severe obstetric complications |
| |
- |
Postpartum levels of activated TAFI (TAFIa) in patient plasmas |
| |
- |
The CRP-VLDL complex, a predictor and marker of DIC, exists in vivo |
| |
- |
Soluble endothelial cell markers (sTM, sEPCR and sVWF) in type 2 diabetes |
| |
- |
The prothrombinase enhancing activity exhibited by VLDL derived from patients with the biphasic APTT waveform is due to increased anionic phospholipid exposure |
| |
- |
A thrombomodulin (TM) gene promoter variant (TM-33G > A) in type 2 diabetes |
| Tokunaga M. |
- |
The possible role of calpain in cancer mediated vascular endothelial cell (vEC) retraction |
| Toledo E. |
- |
Cost analysis of the treatment of patients with post–thrombotic syndrome in Brazil |
| Tolle A. R. |
- |
Relation of changes in D-dimer and other coagulation markers with changes in Marder Score after treatment of acute venous thrombosis with the low molecular weight heparin Certoparin or unfractionated heparin |
| Tollefsen D. |
- |
Heparin cofactor II deficiency in mice |
| Tomás J. F. |
- |
Hypercoagulability in cerebrovascular disease (CD): factor V Leiden, prothrombin G20210A and MTHFR C677T mutations and polymorphism in the annexin V kozac sequence |
| |
- |
Retrospective analysis of heritable thrombophilia in 90 children with Legg-Perthes disease |
| |
- |
TNF-alpha promoter polymorphisms (-238 and -308) in patients with cerebrovascular disease |
| Tomasi C. |
- |
Long-term clinical outcome of patients with pulmonary embolism: a prospective, multicenter study |
| |
- |
Incidence of newly diagnosed cancer after three months or one year of oral anticoagulation for a first episode of idiopathic venous thromboembolism |
| Tomic I. |
- |
Construction and characterization of a new recombinant plasminogen activator composed of an antifibrin single-chain antibody and a low molecular weight form single-chain urokinase |
| Tominc U. |
- |
Comparison of magnetic resonance characteristics of the vessel wall between patients with classic and dilatative atherosclerosis |
| Tomiyama Y. |
- |
Demonstration of activation of integrin aIIbb3 by inside-out signaling in a megakaryocytic cell line, CMK |
| |
- |
Interaction of CD47 with SHPS-1 negatively regulates platelet function |
| |
- |
Analysis of Arg-Gly-Asp contact sites in the av subunit of integrin avb3 employing single amino acid mutations |
| Tomkowski W. Z. |
- |
Compression ultrasound in diagnosis of asymptomatic deep venous thrombosis |
| Tomkowski W. |
- |
Fondaparinux vs. placebo for the prevention of venous thromboembolism in acutely ill medical patients (artemis) |
| Tomokiyo K. |
- |
VWF/FVIII concentrate enhances platelet adhesion onto a surface of immobilized collagen under flow conditions |
| Tonda R. |
- |
Hemostatic effect of activated recombinant factor VII (rFVIIa) in liver disease: studies in an in vitro model |
| Tonelli F. |
- |
A clinical outcome-based prospective study on venous thromboembolism in cancer surgery: the @RISTOS project |
| Tonetta S. |
- |
Continuing clinical evaluation of an advanced category recombinant FVIII, antihemophilic factor (recombinant) plasma/albumin-free method (rAHF-PFM) in previously treated patients (PTPs) |
| |
- |
Clinical evaluation of an advanced category recombinant FVIII, anti-hemophilic factor (recombinant) plasma/albumin-free method (rAHF-PFM) in surgical settings |
| Toniato E. |
- |
NAD(P)H oxidase C242T gene variations and cardiovascular protection |
| Tonn T. |
- |
Developing hematopoietic stem cells as targets for gene therapy of hemophilia A |
| |
- |
Intracellular trafficking of native, full-length, and B-domain-deleted coagulation factor VIII (FVIII) in mammalian cells |
| Toomey J. |
- |
Potentiation of aggregation through the stimulation of platelet P2X1 receptors |
| Toorians A. W. F. T. |
- |
Venous thrombosis and APC resistance during hormone treatment in male-to-female transsexuals |
| Topcuoglu P. |
- |
The relation of activated protein C resistance with ABO blood groups |
| Topf H. G. |
- |
Disseminated intravascular coagulation after varicella infection |
| Topol E. J. |
- |
High prevalence of aspirin resistance in patients with a history of myocardial infarction |
| Toporski J. |
- |
Recombinant activated coagulation factor VII for the treatment of spontaneous bleeding in a girl with inhibitors developed after autologus bone marrow transplantation |
| Toral A. |
- |
Hemostatic markers in nonrheumatic atrial fibrillation patients without anticoagulant therapy |
| Torchet M. F. |
- |
Treatment of patients with inhibitors with FEIBA: the French experience from 1995 to 1999 |
| |
- |
Safety and efficacy of Fibrogammin P® for the treatment of patients with severe FXIII deficiency |
| Torelli G. |
- |
Elevated plasma levels of factor VIII in women with early recurrent miscarriage |
| |
- |
Reduced platelet sensitivity to nitric oxide donors in patients with a history of preeclampsia |
| Tormene D. |
- |
The incidence of venous thromboembolism in double-heterozygous carriers of antithrombin, protein C and protein S deficiency and HR2 haplotype |
| |
- |
The incidence of venous thromboembolism in homozygous or double heterozygous carriers of the factor V Leiden mutation, prothrombin 20210 A mutation and HR2 aplotype: interim report |
| Tormene D. |
- |
Below-knee elastic compression stockings for prevention of the post–thrombotic syndrome in patients with proximal-vein thrombosis: a prospective controlled randomized study |
| Tormene D. |
- |
The incidence of venous thromboembolism in carriers of single identified prothrombin G20210A: a retrospective cohort study |
| Tormene D. |
- |
Correlation between internal carotid artery stenosis and hematological risk factors for thrombosis (CAST study): final results |
| |
- |
Impaired interaction of protein C Gla domain variants with the endothelial cell protein C receptor (EPCR) |
| Tornehave D. |
- |
Anti-apoptotic effect of coagulation factor VIIa |
| Torrano-Masetti L. |
- |
Thrombotic risk in first-degree relatives of factor V Leiden (FVL) and factor II G20210A carriers |
| |
- |
Psychologic impact of thrombophilia screening in asymptomatic relatives of carriers of prothrombotic mutations |
| Torre S. |
- |
Transdermal hormone replacement therapy does not affect hemostasis and inflammation |
| Torres A. |
- |
Increased tissue factor expression in monocytes from patients with anti-phospholipid syndrome depends on NFkB activation |
| |
- |
A promising therapeutic strategy in acute promyelocytic leukemia (APL): disruption of MEK/ERK, arsenic and retinoids |
| Torti M. |
- |
Activation of p38 MAP kinase in human platelets stimulated by von Willebrand factor |
| Toschi V. |
- |
Platelet-associated Tissue Factor: modulation of cell surface expression by platelet agonists |
| Tosetto A. |
- |
Evaluation of a new quantitative, rapid test (VWF-LIA) for the diagnosis of type 1 VWD |
| Tosetto A. |
- |
Plasma-derived FXIII concentrate is as safe and effective as placenta-derived FXIII concentrate for the treatment of inherited FXIII deficiency |
| Tosetto A. |
- |
Association between fibrinogen levels and fibrinogen G-455 A polymorphism and preclinical atherosclerosis in the general population |
| Tosetto A. |
- |
Sensitivity and specificity of PFA-100® vs. bleeding time in the diagnosis of type 1 von Willebrand disease (VWD) |
| Tosetto A. |
- |
Comparison of hemorrhagic symptoms in obligatory carriers of type 1 and type 3 von willebrand disease (VWD): results from a collaborative, international, multicenter study |
| Tosetto A. |
- |
The Factor V HR2 haplotype and the risk of venous thrombosis: a metanalysis |
| |
- |
Clinical presentation of type 1 von Willebrand disease (VWD) in obligatory carriers: final results from a collaborative, international, multicenter study |
| Totani L. |
- |
SRC-dependent signaling is a key step in the process of autoregulation of Mac-1 adhesive function in human PMN |
| Totani L. |
- |
Beta-2 integrin adhesion triggered by E-selectin in human PMN: role of SRC kinases and of an unidentified receptor |
| Toth-Zsamboki E. |
- |
P2X1-induced activation of Ca2+ calmodulin leads to myosin light chain and ERK2 phosphorylation in human platelets |
| Toth-Zsamboki E. |
- |
Overexpression of the platelet P2X1 ion channel in transgenic mice generates a novel prothrombotic phenotype |
| Touat Z. |
- |
Smooth muscle cell recolonization of the aneurysmal thrombus is prevented by storage of leukocyte elastase in fibrin matrix |
| Touka M. J. |
- |
Functional studies of P-selectin polymorphism's associated with coronary diseases |
| Toulon P. |
- |
Coagulation and endothelium activation in patients with scrub typhus |
| Toulon P. A. |
- |
Multicenter evaluation of a new polymer tube (Vacuette Sandwich) for coagulation testing. Effect on routine coagulation tests and on plasma levels of markers of coagulation activation |
| Toulon P. |
- |
Acquired protein S deficiency in HIV-infected patients is corrected under HAART |
| |
- |
Genetic polymorphisms and the risk of development of ischemic stroke. Result of a case control study |
| Tournois C. |
- |
Influence of R353Q factor VII gene polymorphism on the plasma FVII levels in a French native population (The Fitenat Study) |
| Tout H. |
- |
Stability of 19 mutated recombinant von Willebrand factor to von Willebrand factor-cleaving protease (ADAMTS13) |
| Townend J. |
- |
Markers of inflammation, coagulation, endothelial damage and platelet activation in chronic renal disease |
| Tracy P. B. |
- |
Factor V endocytosed and retained by megakaryocytes is specifically proteolytically processed by an intracellular protease to form the platelet-derived factor V pool |
| |
- |
Quantification, as well as functional and phenotypic characterization, of baboon platelet- and plasma-derived factor V demonstrate near identity with human factor V pools |
| Tracy R. P. |
- |
Intracellular adhesion molecule-1 is associated with cardiovascular disease in elderly men and women |
| |
- |
C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: the Cardiovascular Health Study (CHS) |
| Tracy P. |
- |
Platelets regulate thrombin generation at their membrane surface through several unique activation-dependent mechanisms |
| Trager I. |
- |
Anti-coagulant effects of direct thrombin inhibitors: compared for potential use in clinical practice |
| |
- |
Prophylaxis of recurrent thromboembolism in a patient with a history of heparin-induced thrombocytopenia with thrombosis, anti-lepirudin antibodies after Bjork-Shiley aortic valve implantation using fondaparinux |
| |
- |
Impact of direct thrombin inhibitors on actions of vitamin K antagonists on analysis with different coagulation parameters: aPTT and PT for argatroban, hirudin and melagatran |
| Tran K. |
- |
Development of small molecule compounds that inhibit PAI-1 activity in vitro and in vivo |
| Tran S. |
- |
Inhibition by prothrombin of individual activated protein C-mediated cleavages in factor Va |
| Tran H. A. |
- |
Vena Tech Vena Caval filters – a 7-year single institution experience and review of the literature |
| Tran K. |
- |
Activated thrombin–activatable fibrinolysis inhibitor (TAFIa) prevents spontaneous fibrinolysis of batroxobin-induced fibrin deposition in rat lungs |
| Tran H. |
- |
Secondary thromboprophylaxis program assessing the efficacy of mini dose warfarin and prothrombin fragment 1 + 2 in selected high risk patients with venous thromboembolism |
| Tranholm M. |
- |
Hemostatic effect of three factor VIIa analogs in antibody-induced hemophilia A in mice |
| Tranholm M. |
- |
In vitro effect of recombinant activated factor VII on thrombin generation and clot formation in blood from patients on vitamin K-antagonist therapy |
| Tranholm M. |
- |
Hemostatic effect of rFVIIa (NovoSeven®) in a mouse model of type 1 von Willebrand disease (VWD) |
| Trasi S. |
- |
Burden of von Willebrand disease in India |
| Trassard S. |
- |
Demonstration of a tissue factor pathway inhibitor-2 (TFPI-2) mRNA synthesis by pure villous cytotrophoblast cells isolated from term human placentas |
| Tratar G. |
- |
Shear rate of plasma flow and fibrin specificity of thrombolytic agent promote thrombolysis of nonretracted and retracted whole blood clots – a MRI study in vitro |
| Tratar G. |
- |
Safety of the transfer of patients on anticoagulant therapy from hospital anticoagulant clinics to general practitioners using a computer-decision support |
| Travin M. I. |
- |
Factor VII levels, coronary artery disease, and MI |
| Treacy M. |
- |
Teicoplanin-dependent platelet antibodies as a cause of severe thrombocytopenia |
| Tremoli E. |
- |
Pentoxifylline prevents spontaneous brain ischemia in stroke-prone rats |
| |
- |
Reactive oxygen species mediate cyclooxygenase-2 induction during monocyte transition into macrophages: critical role for NADPH oxidase |
| |
- |
Post-treatment of rats with simvastatin affords brain protection after focal ischemia as assessed by magnetic resonance imaging |
| |
- |
Platelet-associated Tissue Factor expression in patients with unstable coronary artery disease |
| |
- |
Platelet-associated Tissue Factor: modulation of cell surface expression by platelet agonists |
| Tremuth L. |
- |
Interacting sites within Talin and the integrin b3 cytoplasmic tail |
| Treppiccione A. |
- |
cAMP inhibits convulxin-induced calcium mobilization; differences with collagen |
| Trevino S. |
- |
Safety and tolerability of argatroban anticoagulation in patients with end-stage renal disease undergoing hemodialysis: a prospective study |
| Trías N. |
- |
Association between recurrent pregnancy loss and prothrombotic gene polymorphisms |
| Trichet C. |
- |
Fatal intra cerebral hemorrhage due to severe vitamin K deficiency disclosing cystic fibrosis |
| |
- |
Clinical and laboratory findings in a new case of congenital amegakaryocytic thrombocytopenia (CAMT) |
| Trieb K. |
- |
Total knee arthroplasty in hemophilic arthropathy |
| Triemstra A. H. M. |
- |
An evaluation of 30 years of hemophilia treatment in the Netherlands |
| Trillard M. |
- |
Increased factor V level and preanalytical coagulation |
| Triplett D. A. |
- |
The high frequency and specificity of the Lupus cofactor effect in a dPT screen |
| Tripodi A. |
- |
Hyperprothrombinemia is associated with enhanced TAFI-mediated inhibition of fibrinolysis |
| |
- |
European concerted action on anti-coagulation (ECAA). Correction of displayed INR on two point-of-care test (POCT) whole blood prothrombin time monitors (CoaguChek Mini and TAS PT-NC) by independent International Sensitivity Index (ISI) calibration |
| |
- |
European action on anti-coagulation – cost effectiveness of computer assisted anti-coagulant dosage |
| |
- |
European concerted action on anti-coagulation (ECAA). reliability of International Normalized Ratios (INR) from CoaguChek mini and TAS PT-NC whole blood point-of-care test monitor systems |
| |
- |
Standardization of activated protein C resistance testing: effect of residual platelets in frozen plasmas assessed with commercial and home made methods |
| |
- |
Thrombin generation assessed as endogenous thrombin potential (ETP) in patients with hyper- or hypo-coagulability. Effects of phospholipids, tissue factor and residual platelets on the measurement performed in platelet-poor and platelet-rich plasma |
| Triscott M. |
- |
The Rapidpoint™ ENOX point-of-care test has strong correlation with anti-Xa levels for detecting the anti-coagulant effects of enoxaparin |
| Tritschler H. |
- |
Long-term RAGE-mediated NF-kB activation in diabetic neuropathy and its role in loss of pain perception |
| Trocherie C. |
- |
Age influence on D-Dimer in a large normal French population: the FITENAT study |
| Troconiz Ch. |
- |
The effect of BIBR 953 ZW, the active form of the oral direct thrombin inhibitor BIBR 1048, on the prolongation of aPTT and ECT in orthopedic patients: a population pharmacodynamic study |
| Tronchere H. |
- |
Lipid rafts in platelet activation processes |
| Tronik-Le Roux D. |
- |
A study of gene expression profiles during megakaryocytopoiesis |
| Tropeano P. F. |
- |
Subcutaneous adjusted-dose unfractionated heparin vs. fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism |
| Trossaert M. |
- |
Evaluation of automated measurement of ristocetin cofactor activity of von Willebrand factor on STA-R® in von willebrand disease: study in 154 patients |
| Trossaert M. |
- |
Analytical validation of the automated measurement on STA-R of the ristocetin cofactor activity (VWF:RCo) of von Willebrand factor |
| Trottini S. |
- |
A comparison between routine plasma INRs and fingerstick whole blood INRs determinations, using three portable self-testing devices (Coagucheck®, Pro-Time®, Gem-PLC®) and a near-patient whole blood device (Thrombotrack®) |
| |
- |
Oral anti-coagulant therapy with POC device and remote computer monitoring in the setting of the Italian National Health System (INHS) |
| |
- |
Clinical quality assessment program for the oral anti-coagulant clinic: preliminary report of a multicentric Italian exercise |
| Trummal K. |
- |
Vipera lebetina factor X activating enzyme – cloning and sequencing |
| Trusheim H. |
- |
An intracellular cofactor of Factor VII activating protease (FSAP) functions as an initiator of blood coagulation |
| Trzeciak M. C. |
- |
In vitro flow cytometry and functional testing of fresh and cryopreserved platelets |
| |
- |
Determination of effective concentrations of recombinant factor VIIa (rFVIIa) for Glanzmann thrombasthenia patients by using thrombin generation in platelet-rich plasma (PRP) and platelet-poor plasma (PPP) |
| Tsai H. M. |
- |
New development in the diagnosis and management of thrombotic microangiopathy |
| Tsai H. |
- |
ADAMTS13 mutations identified in familial TTP patients result in loss of VWF-cleaving protease activity |
| Tsakiri M. |
- |
Comparison and diagnostic value of two different D-dimer methods in the clinical laboratory |
| Tsakiris D. A. |
- |
VCAM-1/VLA-4 up-regulation as a perpetuation loop in patients with chronic graft vs. host disease? |
| Tschopp T. |
- |
The active conformations of Factor VIIa and Factor IXa: biochemical, biophysical, chemical and crystallographic studies |
| Tseng Y. L. |
- |
A snake venom metalloproteinase reduces neutrophil-platelet adhesion through down-regulation of PSGL-1 expression |
| Tsigkas D. |
- |
Genetic risk factors in patients with myocardial infarction and correlation with echocardiographic study |
| Tsoukala C. |
- |
A case of an acquired inhibitor of Factor XIII |
| Tsouknos A. |
- |
Endothelial cells cocultured with monocytes are activated to support the adhesion of flowing leukocytes by a combination of TNF-a IFN-g and TGF-b1, a process that is progressively ablated as monocytes differentiate into macrophages |
| Tsourkala C. |
- |
Recombinant FVIIa for the treatment of severe bleeding in patients with hematological malignancies and thrombocytopenia |
| Tsoutsoumanou K. |
- |
Correlation between SVCAM, SICAM plasma levels, the outcome of treadmill test and the systolic function of left ventricular (LV) in patients with coronary artery disease |
| |
- |
Smoking and abnormalities of coagulation-fibrinolysis in patients with coronary heart disease |
| |
- |
Is there an hypercoagulable state after treadmill exercise in patients with atrial fibrillation? |
| |
- |
Inflammatory factors in patients with acute coronary syndromes. Is there any fluctuation with smoking or cholesterol levels? |
| |
- |
Obesity and coagulation. Is there any correlation? |
| |
- |
Levels of plasma tissue activator plasminogen (tPA)- A useful marker in the differential diagnosis of chest pain (marker of plaque destabilization) |
| |
- |
Correlation SVCAM, SICAM plasma levels with the outcome of treadmill test and with attitudinal factors for coronary artery disease in patients without previous history of ischemic heart disease |
| Tsuji T. |
- |
Successful argatroban-anticoagulant management for left ventricular assist system implantation in two patients with heparin-induced thrombocytopenia type II |
| Tsunoda C. |
- |
Differences in perioperative coagulation between Japanese and other ethnic groups undergoing laparoscopic cholecystectomy |
| Tsuruta K. |
- |
Phase I study of a novel recombinant human soluble thrombomodulin, ART-123 |
| Tsutsumi S. |
- |
Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747, a novel P2Y12 receptor antagonist |
| Tsutsumi T. |
- |
Involvement of VEGF-C/flt-4 system in therapeutic angiogenesis of FGF-2 gene transfer in murine ischemic hind limb |
| Tsutsumi N. |
- |
Platelet-derived growth factor receptor-alpha signaling is required for therapeutic angiogenesis induced by fibroblast growth factor-2 |
| Tsybulkin A. |
- |
Lupus anticoagulant as marker of immune system dysfunction in patients with multiple sclerosis |
| Tuddenham E. G. D. |
- |
Two novel mutations in severe factor VII deficiency |
| |
- |
Coagulation proteases factor Xa and factor VIIa do not mobilize intracellular calcium stores in human dermal fibroblasts |
| Tuddenham E. G. |
- |
Expression of human tissue factor pathway inhibitor and hirudin fusion proteins on mouse vascular smooth muscle cells inhibits vascular remodeling after wire-induced carotid artery injury |
| Tuddenham E. G. D. |
- |
Functional characterization of recombinant Factor V Liverpool: Ile350Thr, a novel mutation associated with thrombosis |
| Tuddenham E. G. |
- |
Targeted expression of tissue factor pathway inhibitor and hirudin fusion proteins to endothelial cells reduces pathology in murine LPS-induced endotoxic shock – a novel model to study vascular inflammation |
| Tuddenham E. G. D. |
- |
Severe thrombophilia in two brothers due to novel combination of mutations in factor V gene producing quantitative deficiency (Glu119Term) and decreased sensitivity to activated protein C due to a novel glycosylation site (Ile359Thr-FV Liverpool) |
| |
- |
Glycoprotein IX Asn45Ser: an ancestral mutation causing Bernard–Soulier syndrome in Europeans? |
| Tulevski I. I. |
- |
Brain natriuretic peptide (BNP) as a predictor of adverse outcome in patients with pulmonary embolism |
| Tuley E. A. |
- |
Characterization of a mixed disulfide intermediate between the propeptide and the mature subunit of von Willebrand Factor during multimer formation |
| Tuluc M. |
- |
Human platelets generate thromboxane A2 upon interaction with immobilized fibrinogen without a requirement for adherence in a Syk-dependent manner |
| Tunali T. |
- |
Effects of 6,7-dihydroxy-3-phenylcoumarin and warfarin on thromboplastin induced experimental disseminated intravascular coagulation |
| Turdo K. |
- |
Low molecular weight heparin (LMWH) in pregnant women with mechanical prosthetic heart valves (MPHV) |
| Turecek P. |
- |
Monitoring the pharmacokinetic of inhibitor-bypassing agents with a new thrombin generation assay |
| Turecek P. L. |
- |
Monitoring the pharmacokinetic of inhibitor-bypassing agents with a new thrombin generation assay |
| |
- |
Changes in ADAMTS13 (vWF cleaving protease) activity after induced acute release of von Willebrand factor |
| Turecek P. L. |
- |
Analytical comparison of recombinant and plasma-derived activated protein C (APC) |
| Turecek P. L. |
- |
Differentiation of factor VIII-specific memory B cells into anti-factor VIII antibody-secreting cells requires direct interaction between memory B cells and activated T cells but is not dependent on factor VIII-specific T cells |
| Turecek P. L. |
- |
Proteases derived from Ficus carica activate human factor X |
| Turecek P. |
- |
Surface exposed mutation W2313A in the C2-domain of FVIII results in defective secretion of otherwise functional protein |
| Turello M. |
- |
Efficacy of high purity, monoclonal factor IX concentrate for continuous infusion in an hemophilia B patient undergoing orthopedic surgery |
| Turenhout E. A. M. |
- |
Novel approaches to determine the characteristics of ADAMTS13 inhibitors in patients with acquired TTP |
| Turkaman G. |
- |
Effect of ergometric exercise on factor VIII coagulant activity in patients with mild and moderate hemophilia A |
| Turner S. |
- |
Mechanotransduction through glycoprotein Iba induces a unique series of morphologic changes in translocating platelets |
| Turner M. |
- |
Involvement of the p110d catalytic subunit of phosphatidylinositol 3-kinase in platelet spreading on fibrinogen |
| Turowiecka Z. |
- |
Antiphospholipid antibodies in patients diagnosed for thrombophilia |
| |
- |
Thrombin activable fibrinolysis inhibitior (TAFI) in patients with obesity |
| Turpie A. G. G. |
- |
No episode of thrombocytopenia after four-week administration of fondaparinux, a new synthetic and selective inhibitor of factor Xa, in the PENTHIFRA-PLUS study |
| |
- |
Ability of d-dimer to reduce the need for diagnostic imaging in patients with suspected pulmonary embolism: A randomized trial |
| |
- |
Peri-procedure management of patients with heart valve replacements who require temporary interruption of warfarin therapy using low-molecular-weight heparin (enoxaparin) |
| |
- |
Non-invasive detection of proximal DVT using bilateral compression ultrasound: methodology for the EXCLAIM study |
| |
- |
Influence of thrombophilia on efficacy of warfarin for prevention of recurrent venous thromboembolism: results from a randomized trial |
| |
- |
Extended thromboprophylaxis with enoxaparin in acutely ill medical patients with prolonged periods of immobilisation: the EXCLAIM study |
| |
- |
Influence of warfarin use on symptoms of fatigue: a randomized cross-over trial |
| Turpie A. G. G. |
- |
Relevance of venographic distal thrombus assessment in venous thromboembolism (VTE) prophylaxis studies: lessons from the fondaparinux (Arixtra®) database in major orthopedic surgery |
| Turpie A. G. G. |
- |
Absence of transaminase increase after 4-week administration of fondaparinux (Arixtra®), a new synthetic and selective inhibitor of factor Xa, in the PENTHIFRA-PLUS study |
| Turpie A.G.G. |
- |
A multinational observational cohort study in hospitalized medical patients of practices in prevention of venous thromboembolism and clinical outcomes: findings of the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) |
| Turpie A. G. G. |
- |
Fondaparinux vs. placebo for the prevention of venous thromboembolism in acutely ill medical patients (artemis) |
| |
- |
Clinical outcomes with the use of unfractionated heparin or low-molecular-weight heparin as perioperative bridging therapy in patients on long-term oral anti-coagulants: Rationale, objectives, and design of a large, long-term study (REGIMEN) |
| Turpie G. |
- |
Evaluating bleeding complications of thromboprophylaxis after hip replacement: a systematic review |
| Turpie A. G. G. |
- |
A risk assessment model for identifying medical patients who should receive thromboprophylaxis |
| Turpie A. G. |
- |
Does DVT exist in Asia? – The AIDA study (assessment of the incidence of Deep Vein Thrombosis in Asia following major orthopedic surgery): study rationale and interim results |
| Turpie A. G. G. |
- |
Low-molecular-weight heparin (LMWH) as bridging anticoagulation in patients who require temporary interruption of warfarin for elective surgery: assessment of a standardized perioperative anticoagulation regimen |
| |
- |
A randomized placebo controlled trial of dalteparin for the prevention of venous thromboembolism in 3706 acutely Ill medical patients: the PREVENT medical thromboprophylaxis study |
| |
- |
Perioperative management of patients on oral anti-coagulants: a systematic review |
| |
- |
Influence of the duration of fondaparinux prophylaxis in preventing venous thromboembolism (VTE) following major orthopedic surgery |
| Tutun U. |
- |
Protein C, S and antithrombin III levels in patients with acute mechanical valve thrombosis |
| Twaddle S. |
- |
The risk of thromboembolism and the effectiveness of prophylactic treatment in thrombophilia patients undergoing major orthopaedic surgery: a systematic review |
| |
- |
Screening for thrombophilia: an economic assessment |
| |
- |
Thrombophilia in pregnancy, combined oral contraceptives and hormone replacement therapy users: a systematic review |
| Tynngård N. |
- |
Effects of anticoagulation, red blood cells and number of platelets on coagulation and clot elasticity measured by free oscillation rheometry |
| Tyurin K. |
- |
Optimal concentrations of inhibitors, zymogens and procofactors of coagulation |
| |
- |
Optimization model for type IV collagen degradation: determination of kinetic constants |
| Tzagaroulaki S. |
- |
Comparison and diagnostic value of two different D-dimer methods in the clinical laboratory |
| Tzolou A. |
- |
Is the G455A polymorphism of the fibrinogen beta gene associated with osteonecrosis? A preliminary report |
